US 10,889,806 B2
Engineered pantothenate kinase variant enzymes
Margie Tabuga Borra-Garske, Palo Alto, CA (US); Oscar Alvizo, Fremont, CA (US); Lillian Jasmine Miller, Saratoga, CA (US); Jesse B. Slaton, Sacramento, CA (US); Aksiniya Lyubenova Petkova, Sunnyvale, CA (US); Nandhitha Subramanian, San Francisco, CA (US); Joshua Kolev, Rahway, NJ (US); Anna Fryszkowska, New York, NY (US); Agustina Rodriguez-Granillo, Rahway, NJ (US); and Grant Murphy, Rahway, NJ (US)
Assigned to Codexis, Inc., Redwood City, CA (US)
Filed by Codexis, Inc., Redwood City, CA (US)
Filed on Jul. 2, 2019, as Appl. No. 16/460,147.
Claims priority of provisional application 62/695,587, filed on Jul. 9, 2018.
Claims priority of provisional application 62/822,301, filed on Mar. 22, 2019.
Prior Publication US 2020/0010815 A1, Jan. 9, 2020
Int. Cl. C12N 9/12 (2006.01)
CPC C12N 9/1205 (2013.01) [C12Y 207/01033 (2013.01)] 29 Claims
 
1. An engineered pantothenate kinase polypeptide comprising an amino acid sequence having at least 85% sequence identity to SEQ ID NO: 2, or to a functional fragment thereof, wherein said polypeptide or fragment thereof comprises an amino acid substitution corresponding to amino acid position 277 and/or 281 in SEQ ID NO: 2, wherein said polypeptide has increased ability to convert ethynyl glyceraldehyde to ethynyl glyceraldehyde phosphate when compared the wild-type polypeptide having the amino acid sequence SEQ ID NO: 2.